Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 5/20 | 0.41 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.35 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.35 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.33 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14655006 | 0.87 | MME (0.42) | MMECSNK2A2CSNK2A1SMYD3SSTR4 | |
| SCHEMBL15906227 | 0.82 | EPHX1 (0.44) | MMECSNK2A2CSNK2A1SSTR4 | |
| SCHEMBL14652098 | 0.79 | OPRL1 (0.36) | MMESMYD3HCRTR2OPRL1OPRM1 | |
| SCHEMBL14652117 | 0.77 | KDM5A (0.38) | MMESMYD3HCRTR2OPRL1OPRM1 | |
| SCHEMBL14652103 | 0.76 | OPRL1 (0.35) | MMESMYD3HCRTR2OPRL1OPRM1 | |
| SCHEMBL14652101 | 0.76 | MME (0.37) | MMESMYD3HCRTR2OPRL1OPRM1 | |
| SCHEMBL14652083 | 0.76 | SMYD3 (0.50) | SMYD3 | |
| SCHEMBL15247301 | 0.75 | SMYD3 (0.38) | SMYD3HCRTR2LMNAL3MBTL1 | |
| SCHEMBL18232512 | 0.75 | SMYD3 (0.38) | SMYD3HCRTR2LMNAL3MBTL1 | |
| SCHEMBL12303982 | 0.70 | DPP4 (0.47) | SMYD3HCRTR2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8791257-B2 | Substituted pyrrolotriazines as protein kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-07-29 | — | — | US | disclosed |
| US-20130023514-A1 | SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023514-A1 | SUBSTITUTED PYRROLOTRIAZINES AS PROTEIN KINASE INHIBITORS | STK25, MAP3K15, MAP3K5 | MME 4725/4885CSNK2A2 123/4885CSNK2A1 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.